Hadron Systems, Inc., a near Princeton, NJ-based biotechnology company focused on developing the techniques and devices to support slow neutron therapy for cancers, including the targeting and ablation of tumor stroma cells, without which tumors cannot form, has received a $5m investment from Mentor Capital, Inc. (OTC Markets: MNTR).
With the transaction, Mentor acquired a 9% interest in Hadron, whose cancer neutron therapy system is classified as a medical device.
The proceeds from the investment will be used to conduct the last part of product test, including late-stage cancer patients, which is planned for September 2012.
FinSMEs
05/05/2011